WO2001074401A3 - Camptothecin complexes - Google Patents

Camptothecin complexes Download PDF

Info

Publication number
WO2001074401A3
WO2001074401A3 PCT/US2001/006829 US0106829W WO0174401A3 WO 2001074401 A3 WO2001074401 A3 WO 2001074401A3 US 0106829 W US0106829 W US 0106829W WO 0174401 A3 WO0174401 A3 WO 0174401A3
Authority
WO
WIPO (PCT)
Prior art keywords
camptothecin
disclosed
complexes
compositions
inventive
Prior art date
Application number
PCT/US2001/006829
Other languages
French (fr)
Other versions
WO2001074401A2 (en
Inventor
Joseph Rubinfeld
Simeon M Wrenn
Original Assignee
Supergen Inc
Joseph Rubinfeld
Simeon M Wrenn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc, Joseph Rubinfeld, Simeon M Wrenn filed Critical Supergen Inc
Priority to EP01914662A priority Critical patent/EP1267936A2/en
Priority to AU2001240024A priority patent/AU2001240024A1/en
Publication of WO2001074401A2 publication Critical patent/WO2001074401A2/en
Publication of WO2001074401A3 publication Critical patent/WO2001074401A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
    • B65G21/00—Supporting or protective framework or housings for endless load-carriers or traction elements of belt or chain conveyors
    • B65G21/10—Supporting or protective framework or housings for endless load-carriers or traction elements of belt or chain conveyors movable, or having interchangeable or relatively movable parts; Devices for moving framework or parts thereof
    • B65G21/14—Supporting or protective framework or housings for endless load-carriers or traction elements of belt or chain conveyors movable, or having interchangeable or relatively movable parts; Devices for moving framework or parts thereof to allow adjustment of length or configuration of load-carrier or traction element

Abstract

Disclosed are compositions that include a camptothecin and an amorphous cyclodextrin. The camptothecin may be substituted or unsubstituted. Also disclosed are methods of treating undesirable or uncontrolled cell proliferation by administering the inventive compositions. Finally, implants including an implant structure and the inventive composition are disclosed.
PCT/US2001/006829 2000-03-31 2001-03-02 Camptothecin complexes WO2001074401A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01914662A EP1267936A2 (en) 2000-03-31 2001-03-02 Camptothecin complexes
AU2001240024A AU2001240024A1 (en) 2000-03-31 2001-03-02 Camptothecin complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53998200A 2000-03-31 2000-03-31
US09/539,982 2000-03-31

Publications (2)

Publication Number Publication Date
WO2001074401A2 WO2001074401A2 (en) 2001-10-11
WO2001074401A3 true WO2001074401A3 (en) 2002-05-02

Family

ID=24153476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006829 WO2001074401A2 (en) 2000-03-31 2001-03-02 Camptothecin complexes

Country Status (3)

Country Link
EP (1) EP1267936A2 (en)
AU (1) AU2001240024A1 (en)
WO (1) WO2001074401A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049322B2 (en) * 2002-02-21 2006-05-23 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
KR20120104412A (en) * 2002-09-06 2012-09-20 인설트 테라페틱스, 인코퍼레이티드 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
US20110207760A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Sn-38 compositions
EP2632264B1 (en) * 2010-10-29 2019-10-02 Health Research, Inc. Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN105561406A (en) * 2016-02-15 2016-05-11 丹阳纳瑞康纳米科技有限公司 Intravascular stent including composite medicine coating

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0623354A1 (en) * 1993-04-26 1994-11-09 Medtronic, Inc. Intravascular stents
WO1999030684A1 (en) * 1997-12-12 1999-06-24 Supergen, Inc. Local delivery of therapeutic agents
WO1999062510A2 (en) * 1998-06-01 1999-12-09 Angiotech Pharmaceuticals, Inc. Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
WO2000000238A1 (en) * 1998-06-26 2000-01-06 Quanam Medical Corporation Topoisomerase inhibitors for prevention of restenosis
US20010021703A1 (en) * 1998-12-30 2001-09-13 Kosak Kenneth M. Biocleavable micelle compositions for use as drug carriers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0623354A1 (en) * 1993-04-26 1994-11-09 Medtronic, Inc. Intravascular stents
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
WO1999030684A1 (en) * 1997-12-12 1999-06-24 Supergen, Inc. Local delivery of therapeutic agents
WO1999062510A2 (en) * 1998-06-01 1999-12-09 Angiotech Pharmaceuticals, Inc. Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
WO2000000238A1 (en) * 1998-06-26 2000-01-06 Quanam Medical Corporation Topoisomerase inhibitors for prevention of restenosis
US20010021703A1 (en) * 1998-12-30 2001-09-13 Kosak Kenneth M. Biocleavable micelle compositions for use as drug carriers

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FRIEDMAN HENRY S ET AL: "Treatment of central nervous system xenografts with camptothecins.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 803, 1996, Conference;Bethesda, Maryland, USA; February 7-10, 1996, discovery to the patient. 1996 New York Academy of Sciences 2 East 63rd Street, New York, New York 10021, USA, pages 210 - 212, XP001053589, ISBN: 1-57331-057-3 *
GIOVANELLA B C ET AL: "Protocols for the treatment of human tumor xenografts with camptothecins.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 803, 1996, Conference;Bethesda, Maryland, USA; February 7-10, 1996, discovery to the patient. 1996 New York Academy of Sciences 2 East 63rd Street, New York, New York 10021, USA, pages 181 - 187, XP001053591, ISBN: 1-57331-057-3 *
JONKMAN-DE VRIES J.D. ET AL: "Pharmaceutical development of (investigational) anticancer agents for parenteral use - A review", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1996, VOL. 22, NO. 6, PAGE(S) 475-494, XP001053466 *
NATELSON ETHAN A ET AL: "Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 803, 1996, Conference;Bethesda, Maryland, USA; February 7-10, 1996, discovery to the patient. 1996 New York Academy of Sciences 2 East 63rd Street, New York, New York 10021, USA, pages 224 - 230, XP001053588, ISBN: 1-57331-057-3 *
SAIJO NAGAHIRO: "Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecan injection) in Japan.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 803, 1996, Conference;Bethesda, Maryland, USA; February 7-10, 1996, discovery to the patient. 1996 New York Academy of Sciences 2 East 63rd Street, New York, New York 10021, USA, pages 292 - 305, XP001053587, ISBN: 1-57331-057-3 *
SHARMA U S ET AL: "PHARMACEUTICAL AND PHYSICAL PROPERTIES OF PACLITAXEL (TAXOL) COMPLEXES WITH CYCLODEXTRINS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 84, no. 10, 1 October 1995 (1995-10-01), pages 1223 - 1230, XP000529731, ISSN: 0022-3549 *
UNDERBERG WJ ET AL: "Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution.", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, VOL. 8, NO. 8-12, PAGE(S) 681-3, XP001053447 *

Also Published As

Publication number Publication date
EP1267936A2 (en) 2003-01-02
AU2001240024A1 (en) 2001-10-15
WO2001074401A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
AU8003800A (en) Methods and compositions for treating neurobehavioral disorders
AU8016200A (en) Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms
WO2000006133A3 (en) Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions
AU2719300A (en) Antimicrobial compositions containing photosensitizers, articles, and methods ofuse
AU4659900A (en) Treating compositions comprising polysaccharides
WO2001012199A3 (en) Methoxyamine potentiation of temozolomide anti-cancer activity
CA2388646A1 (en) Methods and compositions utilizing quinazolinones
EP2260835A3 (en) Composition for proteasome inhibition
GB9903216D0 (en) Preservative compounds,compositions and methods of making and using the same
WO2003094837A3 (en) Treatments with autologous fibroblast
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
AU5601300A (en) Method and compositions for treating and preventing retinal damage
WO2000066528A3 (en) Quinones for treatment of diseases
HK1047707A1 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
AU7360000A (en) Methods and compositions for preventing and treating prostate disorders
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU2002367023A1 (en) Compositions and methods for treating heart failure
WO2001074401A3 (en) Camptothecin complexes
MXPA02003232A (en) Compositions and methods for altering gene expression.
AU4033900A (en) Compositions and methods for treating cell proliferation disorders
AU2002365057A1 (en) Compositions and methods for treating heart failure
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
WO2002040001A3 (en) Compositions for treatment of malignant effusions comprising a biocompatible polymer and antineoplastic taxane
WO2003007914A3 (en) Biocompatible polymer containing composition for treatment of prostate cancers
AU3065299A (en) Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001914662

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001914662

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP